cln-081,anivantamab,mobocertinib
cullinan oncology,otsuka,janssen,takeda
['cln 081 ', 'sclc', 'nsclc']
amivantamab and movocertinib approved in 2nd line egfr ex20ins nsclc. cln 081 a new player!! promising activity (mpfa 10 months) with good safety profile and opening potential opportunities for sequential treatment approaches on this disease #asco2022 
Medical Oncologist - Thoracic tumors. Personalized treatment approches @EORTC